Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Prostate cancer in 2016

Improved outcomes and precision medicine come within reach

Nature Reviews Urology volume 14, pages 71–72 (2017)Cite this article

Subjects

2016 was an important year for prostate cancer research. New clinical data highlight the need for personalized treatment across clinical disease states and have changed clinical practice for men with metastatic disease. Molecular studies have characterized tumour heterogeneity and informed biomarker development for advanced disease and research into mechanisms of treatment resistance.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

    Article  PubMed  Google Scholar 

  2. James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sweeney, C. L. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2016).

    Article  Google Scholar 

  4. Sweeney, C. et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial [abstract 720PD]. Ann. Oncol. 27 (Suppl. 6), vi243–vi265 (2016).

    Google Scholar 

  5. Vale, C. L. et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 17, 243–256 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215–1228 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wyatt, A. W. et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2, 1598–1606 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369–378 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cora N. Sternberg is at the San Camillo and Forlanini Hospitals, Medical Oncology, Pavilion Flajani 1, Circonvallazione Gianicolense 87, Rome 00152, Italy.,

    Cora N. Sternberg

  2. Division of Medical Oncology, Himisha Beltran is at the Weill Cornell Medical College, 525 East 68th Street, Box 403, New York 10021, USA.,

    Himisha Beltran

Authors
  1. Cora N. Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Himisha Beltran
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors researched data for the article, made substantial contributions to discussion of its content, wrote the article and reviewed/edited the manuscript before submission.

Corresponding authors

Correspondence to Cora N. Sternberg or Himisha Beltran.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sternberg, C., Beltran, H. Improved outcomes and precision medicine come within reach. Nat Rev Urol 14, 71–72 (2017). https://doi.org/10.1038/nrurol.2016.270

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.270

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer